MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

医学 内科学 危险系数 临床终点 队列 安慰剂 耐受性 中期分析 乳腺癌 富维斯特朗 人口 肿瘤科 随机对照试验 癌症 不利影响 置信区间 雌激素受体 病理 替代医学 环境卫生
作者
Qing Yuan Zhang,Tao Sun,Yong Mei Yin,Hui Ping Li,Min Yan,Zhong Sheng Tong,Christina P. Oppermann,Yun Peng Liu,Rômulo Leopoldo de Paula Costa,Man Li,Ying Cheng,Qu Chang Ouyang,Xi Chen,Ning Liao,Xin Hong Wu,Xiao Jia Wang,J. Feng,Roberto Hegg,Govind Babu Kanakasetty,Maria Antonia Coccia-Portugal
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE Publishing]
卷期号:12: 1758835920963925-1758835920963925 被引量:107
标识
DOI:10.1177/1758835920963925
摘要

Aim: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) from China, Brazil, India, and South Africa. Methods: This randomized, double-blind, phase III study was conducted between 9 December 2016 and 29 March 2019. Postmenopausal women with HR-positive, HER2-negative ABC with no prior systemic therapy in an advanced setting (cohort A) or progression on prior ET (cohort B) received abemaciclib (150 mg twice daily) or placebo plus: anastrozole (1 mg/day) or letrozole (2.5 mg/day) (cohort A) or fulvestrant (500 mg per label) (cohort B). The primary endpoint was progression-free survival (PFS) in cohort A, analyzed using the stratified log-rank test. Secondary endpoints were PFS in cohort B (key secondary endpoint), objective response rate (ORR), and safety. This interim analysis was planned after 119 PFS events in cohort A. Results: In cohort A, 207 patients were randomly assigned to the abemaciclib arm and 99 to the placebo arm. Abemaciclib significantly improved PFS versus placebo (median: not reached versus 14.7 months; hazard ratio 0.499; 95% confidence intervals (CI) 0.346–0.719; p = 0.0001). ORR was 65.9% in the abemaciclib arm and 36.1% in the placebo arm ( p < 0.0001, measurable disease population). In cohort B, 104 patients were randomly assigned to the abemaciclib arm and 53 to the placebo arm. Abemaciclib significantly improved PFS versus placebo (median: 11.5 versus 5.6 months; hazard ratio 0.376; 95% CI 0.240–0.588; p < 0.0001). ORR was 50.0% in the abemaciclib arm and 10.5% in the placebo arm ( p < 0.0001, measurable disease population). The most frequent grade ⩾3 adverse events in the abemaciclib arms were neutropenia, leukopenia, and anemia (both cohorts), and lymphocytopenia (cohort B). Conclusion: The addition of abemaciclib to ET demonstrated significant and clinically meaningful improvement in PFS and ORR, without new safety signals observed in this population. Trial Registration: ClinicalTrials.gov identifier: NCT02763566.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
李健的粉丝团团长的应助被Eli采纳,获得10
1秒前
Maestro_S的应助被AA采纳,获得10
2秒前
荼蘼发布了新的文献求助10
2秒前
Zz发布了新的文献求助10
2秒前
asd459完成签到,获得积分10
3秒前
晨晨完成签到,获得积分10
3秒前
3秒前
3秒前
完美焦发布了新的文献求助10
4秒前
Rea完成签到,获得积分10
4秒前
闪闪的映波完成签到,获得积分10
5秒前
6秒前
传奇3的应助被primriy采纳,获得10
6秒前
成就完成签到,获得积分10
7秒前
7秒前
深情安青的应助被猫猫大侠采纳,获得10
8秒前
8秒前
万万万完成签到,获得积分10
10秒前
tiantian完成签到,获得积分20
11秒前
12秒前
科研通AI2S的应助被BAEKHYUNLUCKY采纳,获得10
12秒前
13秒前
13秒前
LiWen发布了新的文献求助10
13秒前
13秒前
14秒前
仁仁仁发布了新的文献求助10
15秒前
荼蘼发布了新的文献求助10
15秒前
15秒前
16秒前
myco的应助被怡然从雪采纳,获得10
16秒前
111完成签到 ,获得积分10
16秒前
JM完成签到,获得积分10
16秒前
zxy的应助被生动万言采纳,获得10
16秒前
AA发布了新的文献求助10
16秒前
ztx完成签到,获得积分10
16秒前
风吹麦浪的应助被雪雪采纳,获得10
17秒前
17秒前
李健的应助被Denmark采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241